slides · global inventory
Diagram
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 23,622
Current window 15,961-15,990
Pages 788
Rows per page 30
Component
15,961-15,990 of 23,622
31
The chart shows a debt maturity ladder with cash and revolver availability.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · The Ask1 hit
36
The slide uses a standard ESG framework to categorize corporate initiatives and business integration.Lazard | Investor Presentation Deck | 46 slides · Lazard
Pitch deck Investor relations Beat · The Ask1 hit
12
The slide uses a process flow diagram to represent the flight profile and energy usage.Lilium | Investor Presentation Deck | 16 slides · Lilium
Conference presentation Investor relations 1 hit
13
The slide uses a chevron-based process flow combined with a status matrix for different regulatory bodies.Lilium | Investor Presentation Deck | 16 slides · Lilium
Conference presentation Investor relations Loop · Why Now1 hit
14
The slide uses a chevron-based process flow aligned with calendar years and specific project milestones (AAR, PRR, PDR, CDR, GT, FF, EIS).Lilium | Investor Presentation Deck | 16 slides · Lilium
Conference presentation Investor relations Loop · Why Now1 hit
05
The slide uses a Gantt-style layout to map drug candidates against clinical development stages.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Beat · Problem1 hit
13
The slide outlines a clinical trial process flow including randomization and expansion phases.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations Loop · Pattern Hunter1 hit
23
The slide outlines a multi-stage clinical trial design (Part A/B to Part C) involving immune activation with various checkpoint inhibitors.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
31
The slide outlines a clinical trial process flow from initial baskets through immune activation to a pivotal phase.MAIA Biotechnology | Investor Presentation Deck | 39 slides · MAIA Biotechnology
Pitch deck Investor relations 1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
07
The slide outlines the technical workflow from sample collection to patient report generation.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
13
The slide uses a horizontal timeline to contrast current (2023-2024) and future (2024-2025) clinical trial phases.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
15
The slide outlines a multi-step diagnostic process involving FIT analysis, automated extraction, qPCR, and AI/ML analysis.Mainz Biomed NV | Investor Presentation Deck | 27 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
06
Includes a process diagram for the test workflow and product imagery.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Product1 hit
07
The slide outlines the technical workflow from sample collection (FIT tube and DNA stabilization tube) through analysis to the final patient report.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
13
The slide uses a process flow to demonstrate the technical workflow of the diagnostic test.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations Beat · Solution1 hit
14
Mainz Biomed NV | Investor Presentation Deck | 28 slidesMainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
16
The slide outlines a multi-step diagnostic process involving FIT analysis and proprietary DNA/mRNA extraction.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
21
Includes a footer note about future feasibility studies for other tests.Mainz Biomed NV | Investor Presentation Deck | 28 slides · Mainz Biomed
Pitch deck Investor relations 1 hit
05
The slide uses a process flow diagram to show the funnel from potential partnerships to active clinical programs.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Beat · Traction1 hit
16
The diagram uses concentric circles to represent clinical phases and color-coded dots to represent cell approaches (allogeneic vs autologous).MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations 1 hit
18
The slide uses a process diagram to anchor the business updates.MaxCyte | Investor Presentation Deck | 19 slides · MaxCyte
Pitch deck Investor relations Loop · Why Now1 hit
07
The central diagram is a circular hub-and-spoke model representing the four pillars, surrounded by studio logos.Nexters | Investor Presentation Deck | 18 slides · GDEV
Pitch deck Investor relations Beat · Business Model1 hit
13
The background includes a shaded area representing 'Indicative revenue dynamic'.Nexters | Investor Presentation Deck | 18 slides · GDEV
Pitch deck Investor relations Loop · Why Now1 hit
06
Uses a Venn diagram to illustrate the intersection of solving for resistance and selectivity.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
07
Uses a before-after-bridge framework to contrast existing therapy failure with Nuvalent's success.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
Uses a visual comparison framework to contrast traditional non-selective kinase inhibitors with the company's selective approach.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
16
The slide details the patient population (N=35) and the subset of response-evaluable patients (N=21) across five dose cohorts.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · TractionLoop · Hypothesis Test1 hit
27
Includes clinical trial data cut-offs and patient enrollment numbers.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit
35
The slide uses a process flow diagram to illustrate patient enrollment and expansion cohorts.Nuvalent | Investor Presentation Deck | 52 slides · Nuvalent
Pitch deck Investor relations Beat · Traction1 hit